Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Takeda Pharmaceuticals America, Inc.

2. Address

Address1
670 Maine Ave SW
 Address2
​Suite 210
City
Washington
 State
DC
 Zip Code
20024
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​Andrew Kaplan
​2026494004
​Andrew.Kaplan@takeda.com
5. Senate ID#
​57954-12
7. Client Name Self Check if client is a state or local government or instrumentality
​Takeda Pharmaceuticals America, Inc.
6. House ID#
​352640002
TYPE OF REPORT 8. Year
​2026
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​1,450,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Andrew Kaplan
 Date
10/20/2026 11:16:59 AM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions
H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions
H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions
H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions
P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions
IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc)
IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028
Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage)
Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency)
Medicaid: Proposals related to access or pricing
GLOBE CMMI Model Executive Order

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Andrew
Kaplan
​
​
Kirsten
Powell
​
​
Nick
Lisowski
​
​
Rebecca
Mandell
​
​
Shelley
Stewart
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions
H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions
S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions
H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions
S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions
S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions
S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions
S.1095 Stop STALLING Act, all pharmaceutical related provisions
S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions
Drug Pricing: Policies pertaining to drug pricing not yet introduced
Plasma: Policies or advocacy in the promotion of protecting access
PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count)
340B: Policies related to 340B not specific to a piece of legislation
PDUFA: Perscription Drug User Fee Act
Global pharmaceutical supply chain operations and manufacturing locations
Bayh-Dole march in rights policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Andrew
Kaplan
​
​
Kirsten
Powell
​
​
Shelley
Stewart
​
​
Nick
Lisowski
​
​
Rebecca
Mandell
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Administration's Global Tax Proposal
Tax incentive issues as they relate to proposed global supply chain bills
Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits

17. House(s) of Congress and Federal agencies Check if None

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Andrew
Kaplan
​
​
Kirsten
Powell
​
​
Nick
Lisowski
​
​
Rebecca
Mandell
​
​
Shelley
Stewart
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Issues related to proposed Tariffs - all pharmaceutical related provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Shelley
Stewart
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code DEF

16. Specific lobbying issues

Discussions around Supply Chain implications

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Shelley
Stewart
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)